Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates

分组1 - Catalyst Pharmaceutical (CPRX) reported quarterly earnings of $0.57 per share, exceeding the Zacks Consensus Estimate of $0.49 per share, compared to a loss of $0.24 per share a year ago, representing an earnings surprise of 16.33% [1] - The company achieved revenues of $128.7 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 4.65%, and showing an increase from $102.69 million in the same quarter last year [2] - Catalyst has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has gained approximately 30.6% since the beginning of the year, outperforming the S&P 500's gain of 21.2% [3] - The current consensus EPS estimate for the upcoming quarter is $0.52 on revenues of $128.41 million, and for the current fiscal year, it is $1.92 on revenues of $472.59 million [7] - The Medical - Drugs industry, to which Catalyst belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]